# Qiang Liu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/qiang-liu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 36,723 |
| Field | Cancer-related molecular mechanisms research |
| h-index | 88 |
| i10-index | 409 |
| Last Known Institution | Hubei University of Medicine |
| OpenAlex ID | https://openalex.org/A5100409479 |
| ORCID iD | https://orcid.org/0000-0002-5451-4862 |
| Works | 901 |

## Researcher papers

- [Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer](https://scholariq.org/papers/trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer/)
- [DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25](https://scholariq.org/papers/dna-of-neutrophil-extracellular-traps-promotes-cancer-metastasis-via-ccdc25/)
- [Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer](https://scholariq.org/papers/primary-results-from-impassion131-a-double-blind-placebo-controlled-randomised/)
- [LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc](https://scholariq.org/papers/lncrna-glcc1-promotes-colorectal-carcinogenesis-and-glucose-metabolism-by/)
- [Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial](https://scholariq.org/papers/pyrotinib-plus-capecitabine-versus-lapatinib-plus-capecitabine-for-the-treatment/)
- [Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer](https://scholariq.org/papers/fusobacterium-nucleatum-derived-succinic-acid-induces-tumor-resistance-to/)
- [Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages](https://scholariq.org/papers/immune-checkpoint-inhibition-overcomes-adcp-induced-immunosuppression-by/)
- [<i>F. nucleatum</i> targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer](https://scholariq.org/papers/i-f-nucleatum-i-targets-lncrna-eno1-it1-to-promote-glycolysis-and-oncogenesis-in/)
- [Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10](https://scholariq.org/papers/mesenchymal-stromal-cells-infusions-improve-refractory-chronic-graft-versus-host/)
- [Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1](https://scholariq.org/papers/tamoxifen-resistant-breast-cancer-cells-are-resistant-to-dna-damaging/)

## Researcher topics

- [Cancer-related molecular mechanisms research](https://scholariq.org/topics/cancer-related-molecular-mechanisms-research/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [MicroRNA in disease regulation](https://scholariq.org/topics/microrna-in-disease-regulation/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Hubei University of Medicine](https://scholariq.org/institutions/hubei-university-of-medicine/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.